This is a preview of subscription content, log in via an institution to check access.
Reference
BioTrends Research Group. Surveyed Physicians Indicate that Xtandi is Prescribed to Nearly One Quarter of Metastatic Castrate-Resistant Prostate Cancer Patients Who Have Failed to Respond to Prior Docetaxel Treatment. Media Release : 6 May 2013. Available from: URL: http://www.bio-trends.com
Rights and permissions
About this article
Cite this article
Physicians prescribing enzalutamide. PharmacoEcon Outcomes News 678, 11 (2013). https://doi.org/10.1007/s40274-013-0412-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0412-8